Alexion Will Submit Soliris BLA By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will await final data from the 12-month SHEPHERD study to submit eculizumab for paroxysmal noctural hemoglobinuria.
You may also be interested in...
Alexion Soliris Could Reach Market By Q1 2007 For Orphan Blood Disorder
Announcement of BLA submission coincides with publication of pivotal data in the New England Journal of Medicine.
Alexion Soliris Could Reach Market By Q1 2007 For Orphan Blood Disorder
Announcement of BLA submission coincides with publication of pivotal data in the New England Journal of Medicine.
Alexion/P&G Pexelizumab Failed Phase III Could Compromise Development Partnership
The APEX-AMI study of pexelizumab in patients with acute myocardial infarction failed to meet its endpoint of reduction in mortality.